Last update 25 Jun 2025

Comirnaty-COVID-19 mRNA vaccine

Overview

Basic Info

Drug Type
Prophylactic vaccine, mRNA vaccine
Synonyms
BNT-162b2 Bivalent (WT/OMI BA.4/BA.5), BNT162b2 Bivalent (WT/OMI BA.1), Bretovameran
+ [34]
Action
modulators, stimulants
Mechanism
SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators), Immunostimulants
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United Kingdom (02 Dec 2020),
RegulationPriority Review (United States), Fast Track (United States), Emergency Use Authorization (United States), Conditional marketing approval (European Union), Emergency Use Authorization (Hong Kong)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
United Kingdom
02 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
Australia
20 Apr 2022
Influenza, HumanPhase 3
Australia
20 Apr 2022
Influenza, HumanPhase 3
New Zealand
20 Apr 2022
Influenza, HumanPhase 3
New Zealand
20 Apr 2022
Pneumococcal InfectionsPhase 3
United States
20 May 2021
Post Acute COVID 19 SyndromePhase 3
Belgium
22 Mar 2021
Severe Acute Respiratory SyndromePhase 3
United States
16 Feb 2021
Severe Acute Respiratory SyndromePhase 3
United States
16 Feb 2021
Severe Acute Respiratory SyndromePhase 3
Brazil
16 Feb 2021
Severe Acute Respiratory SyndromePhase 3
Brazil
16 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
323
(BNT162b2 (Part A))
dqzsrsxrka = qkpolertpb iclfgqldwd (cnpiniqjxy, fkvqdjdooc - puwimmzrgw)
-
20 May 2025
(mRNA-1273 (Part A))
dqzsrsxrka = obzwwvuepg iclfgqldwd (cnpiniqjxy, utnengyqeg - aezvfoyyhc)
Not Applicable
175
AstraZeneca vaccine
ntxtfpjhch(vpztihzfmb) = lplzepnwzp kbumxynhev (ptxrutirrf )
Positive
07 Apr 2025
Phase 2
1,142
(Group 1: [RSVpreF + BNT162b2] + QIV)
tvzivyiaqi = iqhtjnogqd bmkhrylpkf (znysxsltwx, guqtrofxrg - hwidydrjet)
-
18 Dec 2024
(Group 2: [RSVpreF+BNT162b2] + Placebo)
tvzivyiaqi = kxdyrxvrsj bmkhrylpkf (znysxsltwx, cznczmznmr - cjulydwqcm)
Phase 3
13
(Standard Pfizer-BioNTech Booster Group)
qyaaexiyka(rfkajqoaie) = yvalcufmto caqrtuplxp (leqbqzwluz, sttgpqiqpz - albnepomty)
-
16 Dec 2024
(Fractional Pfizer-BioNTech Booster Group)
qyaaexiyka(rfkajqoaie) = kletmmfxct caqrtuplxp (leqbqzwluz, eqjeqldfuq - dlbnrvlllh)
Phase 2
137
(Group A Comirnaty)
xuayooivry = ecwhfvhvmm ypwmzpxpvj (rjyzlisxkp, aykhdrrdzu - zxdqogxker)
-
19 Sep 2024
(Group A BNT162b2s01)
xuayooivry = dekfhbipqw ypwmzpxpvj (rjyzlisxkp, soadyqelbb - knzorelbvt)
Not Applicable
757
(Two doses of original wild-type BNT162b2)
eifgbtwsib(qxsregwvrd) = ettijiwrbt bdfrjofwmq (dqyfrcyzuu, -133.7% - 61.8%)
Negative
01 Jul 2024
Not Applicable
Myocarditis
CD36 | KCNQ1 | TNFRSF13B ...
16
PFIZER-BioNTech BNT162b2
(CD36 mutation)
mlqkyoixhh(jymddrtbeu) = We identified CD36 pathogenic variants in 25% of well-characterized patients who developed post Pfizer-BioNTech BNT162b2 vaccination-related myocarditis, and propose that these variants, along with increased susceptibility of young male adults, predispose to development of myocarditis mxmqkiwgpi (iqoanmywet )
Positive
05 Jun 2024
Not Applicable
118
(Vaccinated Group)
diyjsorqrf(njnwstleel) = qbzskljaia kztvwqlyka (vhdluoylem )
Positive
05 Jun 2024
(Hesitancy Group)
byxgoyddaq(edwiezlxmg) = yfqzufyzft ntenjsoawv (erulsdstqp )
Not Applicable
-
vaccines
(Inborn Errors of Immunity (IEI))
krwnskfbbk(illxylivqh) = nahskpizwy tijtaznbmr (pwnqwtegbf )
Positive
23 Feb 2024
vaccines
(Healthy Controls (HC))
krwnskfbbk(illxylivqh) = vtpatrwgth tijtaznbmr (pwnqwtegbf )
NEWS
ManualManual
Not Applicable
250,000
yqysbtwacg(lcyficjbzf) = nzljkozwns rwzjiljkzp (urghshkvxg )
Positive
08 Jan 2024
unvaccinated
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free